PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s stock price was down 2% during trading on Friday. The company traded as low as $0.3865 and last traded at $0.3974. Approximately 214,131 shares traded hands during trading, an increase of 2,325% from the average session volume of 8,831 shares. The stock had previously closed at $0.4056.
PharmaCyte Biotech Price Performance
The business’s fifty day moving average is $0.49 and its two-hundred day moving average is $0.64.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a development-stage biotechnology company focused on cancer therapies. Its principal research program has centered on pancreatic cancer and the company’s Cell-in-a-Box technology, which uses encapsulated genetically engineered cells designed to convert ifosfamide into cancer-fighting metabolites at or near a tumor.
The company has investigated this approach as a potential treatment for locally advanced, inoperable pancreatic cancer. PharmaCyte Biotech has not been known for marketing an approved commercial product, and its activities have primarily involved preclinical research, clinical development, regulatory work and collaboration with technology providers.
Previously known as Nuvilex, the company adopted the PharmaCyte Biotech name as it shifted its focus toward oncology.
See Also
- Five stocks we like better than PharmaCyte Biotech
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
